Trials / Completed
CompletedNCT02998450
A Study of IMR-687 in Healthy Adult Volunteers
A Phase 1a Study of IMR-687 in Healthy Adult Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- Cardurion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this Phase 1a, first in human, randomized, double-blind, placebo-controlled study is to evaluate the safety, tolerability, PK and PD profile of the orally administered IMR-687 in healthy adult subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IMR-687 | 1 of 6 possible single doses administered orally following overnight fast |
| DRUG | Placebo Oral Capsule | Placebo oral capsule with 50 mg microcrystalline cellulose in capsules identical to those used for the active pharmaceutical ingredient. |
Timeline
- Start date
- 2016-10-18
- Primary completion
- 2017-07-08
- Completion
- 2017-07-08
- First posted
- 2016-12-20
- Last updated
- 2025-05-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02998450. Inclusion in this directory is not an endorsement.